Abstract: An objective of the present invention is to provide compounds and pharmaceuticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; R1, R2, and R3 represent H, OH, or optionally substituted alkoxy; R4 represents H; R5, R6, R7, and R8 represent H, Hal, alkyl or the like; and R9 represents, e.g., alkyl substituted by t-butyl or the like.

Abstract: Genes encoding a human PLC-.alpha. polypeptide are provided. An expression vector containing these genes and a transformant having the expression vector are provided. The human PLC-.alpha. polypeptide can be produced by cultivating the transformant. The human PLC-.alpha. polypeptide is useful as an anti-inflammatory agent. Furthermore, a measurement system for conducting clinical evaluation of canceration can be constructed by using the PLC-.alpha. polypeptide.